Lexaria Bioscience
LEXX
12 hedge funds and large institutions have $1.41M invested in Lexaria Bioscience in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
0.26% more ownership
Funds ownership: 7.69% → 7.94% (+0.26%)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
8% less funds holding
Funds holding: 13 → 12 (-1)
24% less capital invested
Capital invested by funds: $1.85M → $1.41M (-$441K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$45.4K |
| 2 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
+$23K |
| 3 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$10.1K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.99K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$19 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EWM
Edge Wealth Management
New York
|
-$13K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$5.55K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ICM
1
Invenomic Capital Management
Boston,
Massachusetts
| $1.06M | +$23K | +6,099 | +2% |
|
2
Geode Capital Management
Boston,
Massachusetts
| $161K | – | – | – |
|
3
Vanguard Group
Malvern,
Pennsylvania
| $112K | – | – | – |
|
|
VF
4
Virtu Financial
New York
| $40K | +$45.4K | +12,026 | New |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $10K | +$6.99K | +1,852 | +154% |
|
|
6
UBS Group
Zurich,
Switzerland
| $9K | -$5.55K | -1,471 | -36% |
|
|
7
1832 Asset Management
Toronto,
Ontario, Canada
| $9K | +$10.1K | +2,686 | New |
|
8
Osaic Holdings
Scottsdale,
Arizona
| $7K | – | – | – |
|
|
9
Wells Fargo
San Francisco,
California
| $3K | +$19 | +5 | +0.5% |
|
|
APC
10
Aspire Private Capital
Cornelius,
North Carolina
| $1K | – | – | – |
|
11
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | – | – | – |
|
|
EWM
12
Edge Wealth Management
New York
| – | -$13K | -3,333 | Closed |
|
LEXX Hedge Fund Activity: Q1 2022 in Review
12 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience (LEXX) for Q1 2022, worth a combined $1.41M — down 24% from $1.85M a quarter earlier.
Fund positioning in LEXX was balanced in Q1 2022: 2 funds opened new positions, 2 closed out, 3 added to existing stakes and 1 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $45.4K. The largest seller was Edge Wealth Management, exiting entirely with an estimated $13K sold.
- 12 institutional investors held Lexaria Bioscience (LEXX) as of Q1 2022, down from 13 in Q4 2021.
- Funds reported $1.41M of Lexaria Bioscience stock for Q1 2022, down 24% quarter-over-quarter.
- 2 funds opened new Lexaria Bioscience positions in Q1 2022 and 2 closed out, a net change of 0 holders.
- The largest Lexaria Bioscience buyer in Q1 2022 was Virtu Financial, an estimated $45.4K added.
- The largest Lexaria Bioscience seller in Q1 2022 was Edge Wealth Management, an estimated $13K sold.
Based on aggregated 13F filings for Q1 2022.